Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials

Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials Background:Clinical trials often focus on the efficacy of biologic agents in the treatment of psoriasis without emphasis on the speed of response.Objective:We evaluated clinical trial data to determine which biologic agents achieve the fastest treatment response.Methods:A review of phase III clinical trials of biologic agents in psoriasis was performed. Speed was determined by analyzing Psoriasis Area and Severity Index (PASI) 75/90 responder curves to estimate the point at which 50% of subjects achieved that outcome, PASI 75/9050. Time to achieve PASI 75/9050 was averaged across trials.Results:Time to achieve PASI 7550, in weeks: brodalumab 210 mg, 3.5; ixekizumab 80 mg Q2 W, 4; secukinumab 300 mg, 5; infliximab 5mg/kg, 5.5; risankizumab 150 mg, 6; guselkumab 100 mg, 6.25; adalimumab 40 mg, 7.25; ustekinumab 45/90 mg, 7.4; certolizumab 400 mg, 7.5; tildrakizumab 100 mg, 9; etanercept 50 mg, 12.5. PASI 9050 responder rate estimations revealed a similar trend.Conclusion:Interleukin-17 inhibitors have a more rapid treatment response compared with other classes. Although speed is important, efficacy, persistence, side effects, cost of treatment, and number of injections are all factors to consider. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Psoriasis and Psoriatic Arthritis SAGE

Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials

Download PDF
7 pages

Loading next page...
 
/lp/sage/speed-of-psoriasis-treatment-response-for-biologic-agents-a-review-of-R5pqSZGIgD

References (42)

Publisher
SAGE
Copyright
© The Author(s) 2021
ISSN
2475-5303
eISSN
2475-5311
DOI
10.1177/2475530321999087
Publisher site
See Article on Publisher Site

Abstract

Background:Clinical trials often focus on the efficacy of biologic agents in the treatment of psoriasis without emphasis on the speed of response.Objective:We evaluated clinical trial data to determine which biologic agents achieve the fastest treatment response.Methods:A review of phase III clinical trials of biologic agents in psoriasis was performed. Speed was determined by analyzing Psoriasis Area and Severity Index (PASI) 75/90 responder curves to estimate the point at which 50% of subjects achieved that outcome, PASI 75/9050. Time to achieve PASI 75/9050 was averaged across trials.Results:Time to achieve PASI 7550, in weeks: brodalumab 210 mg, 3.5; ixekizumab 80 mg Q2 W, 4; secukinumab 300 mg, 5; infliximab 5mg/kg, 5.5; risankizumab 150 mg, 6; guselkumab 100 mg, 6.25; adalimumab 40 mg, 7.25; ustekinumab 45/90 mg, 7.4; certolizumab 400 mg, 7.5; tildrakizumab 100 mg, 9; etanercept 50 mg, 12.5. PASI 9050 responder rate estimations revealed a similar trend.Conclusion:Interleukin-17 inhibitors have a more rapid treatment response compared with other classes. Although speed is important, efficacy, persistence, side effects, cost of treatment, and number of injections are all factors to consider.

Journal

Journal of Psoriasis and Psoriatic Arthritis – SAGE

Published: Apr 1, 2021

Keywords: biologic agents; clinical trials; outcomes; pharmacology; psoriasis; speed of response

There are no references for this article.